Tuesday, August 17, 2021

Actuate Therapeutics announced recently that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for 9-ING-41 injection for the treatment of pancreatic cancer. 9-ING-41 is Actuate’s proprietary small molecule glycogen synthase kinase-3 beta (GSK-3β) inhibitor which is being developed for the treatment of adults and children with advanced refractory cancers.

UI Pharmaceuticals is proud to have been able to support Actuate Therapeutics Inc. by manufacturing clinical drug supplies of Actuate’s investigational drug therapy 9-ING-41. We stand ready to collaborate with all our clients trying to accelerate their novel treatments through human clinical trials and into the marketplace.

About UI Pharmaceuticals:

UI Pharmaceuticals is the longest and most experienced university-affiliated FDA-registered pharmaceutical manufacturing facility in the United States that produces both sterile and non-sterile dosage forms, we have been developing formulations, manufacturing products, and conducting analytical testing for almost 45 years.  UI Pharmaceuticals has a wide range of clients, partners, and collaborators that include both the U.S. and international companies, start-up organizations to mid-tier biotech companies, as well as government agencies.

UI Pharmaceuticals can support the development, manufacture, and all associated testing of preclinical, clinical, and commercial products.

About Actuate Therapeutics, Inc.:

Actuate is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for cancers and inflammatory diseases.  For additional information, please visit the Company’s website at http://www.actuatetherapeutics.com